Category: Presentation

How to Grow Your Scientific Business from Referrals Only to Sales Ready

How to Grow Your Scientific Business from Referrals Only to Sales Ready
Bindu Joshi
CEO & Founder
Josh.i
We will be discussing business growth strategies that scientific businesses can use to grow their business from referrals only to commercial ready. Many scientific businesses are typically owned by scientists (not businessmen/women), and offer innovative, niche services/products that they’re uniquely skilled at and passionate about. We’re neither trained nor interested in learning the skills of running a business. So, over time, the demands of running the business lead to overwhelm, frustration and stress. We will discuss strategies and tactics for business growth to get out of this grind and enjoy your business success.

 

To see this content, please login

Using Lean Methods in Managing a Successful Career and Job Search

Event Information

Event Topic:
Using Lean Methods in Managing a Successful Career and Job Search.

Speaker:
Larry Stevens

Event Description:
Mr. Stevens is an Operations Executive with more than 20 years of experience in the use of LEAN methods in business, personal, career search and career planning. He has led operations, manufacturing, materials/global supply chains, quality and regulatory functions. Mr. Stevens has served in multiple medical device and technology firms from early-stage start-up to multi-billion multi-national conglomerates in senior roles. Mr. Stevens received his B.S. in Technical Management from DeVry University, is a Certified Business Manager, Certified in Lean-Six Sigma, and Certified in Scaling Agile Framework Portfolio, and Certified in Program, and Project Manager.

To see this content, please login

The Apple Heart Study: Transforming clinical trial conduct.

The Apple Heart Study: Transforming clinical trial conduct.

Ken Mahaffey, MD

October 8, 2019
6-9PM, Wilson Sonsini Goodrich & Rosati

The Apple Heart Study was a pragmatic, virtual study of over 400,000 participants to evaluate the Apple Watch ability to detect irregular heart rhythms. The innovative design and operational success will be discussed and the results presented.

Dr. Mahaffey is the Vice-Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR). SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials. SCCR has expertise in mobile and digital technology investigation. Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation.

Dr. Mahaffey also studies the methodology of clinical trials including the standardization of the definition of MI used in clinical trials, the adjudication of clinical endpoints, and the evaluation of evidence-based operations. He works with the FDA and chaired the MI and Death Definitions Working Group in the Standardized Data Collection for Cardiovascular Trials Initiative. Dr. Mahaffey is a member of the Stanford University Institutional Review Board.

Event Speaker Bio:

Dr. Mahaffey is the Vice Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR). SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials. SCCR has expertise in mobile and digital technology investigation. Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation. Dr. Mahaffey also studies the methodology of clinical trials including the standardization of the definition of MI used in clinical trials, the adjudication of clinical endpoints, and the evaluation of evidenced-based operations. He works with the FDA and chaired the MI and Death Definitions Working Group in the Standardized Data Collection for Cardiovascular Trials Initiative. Dr. Mahaffey is a member of the Stanford University Institutional Review Board.

To see this content, please login

The Odyssey of an Orphan Device – Eclipse Regenesis’ Short Bowel Syndrome Solution

The Odyssey of an Orphan Device – Eclipse Regenesis’ Short Bowel Syndrome Solution
Andre Bessette

Date(s) – 09/10/19
6:00 pm – 9:00 pm

Event Description:
Eclipse Regenesis, Inc. is developing the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS), a malabsorption disorder caused by a lack of functional small intestine. Current chronic therapies for SBS include expensive medication and intestinal surgery, which come at a staggering average 5-year cost of $1.6M per patient. Via distraction enterogenesis, the Eclipse XL1 System is able to harness the body’s own tissue regenerative capabilities to produce new, fully functional intestine in vivo. The Eclipse XL1 is the first device based solution for SBS, which is a rare orphan disease market that has been dominated by biotech. From it’s birth in a lab at UCLA to incubation at Stanford and now final emergence as a Bay Area start up, Eclipse’s odyssey touches on many of the current medtech industry challenges of getting a surgeon’s brilliant idea translated into clinical reality to address a syndrome that has no solution today.

Event Speaker Bio:

Andre Bessette, CEO, Eclipse Regenesis, Inc.

Andre Bessette has over 20 years of medical device industry experience with a broad range of applications including orthopedics, sports medicine, oncology, general surgery, plastic surgery, cardiology, pain management, and ENT. He has held various leadership positions in engineering, operations, finance, clinical, sales and marketing throughout his career. Currently, he is Co-Founder and Chief Executive Officer of Eclipse Regenesis, Inc. based in Menlo Park, CA. Prior to Eclipse, he was the Chief Commercial Officer and Executive Vice President for Vantage Surgical Systems. Vantage was an early stage development company focused on a novel minimally invasive robotic surgical systems. Before that, he was Vice President of Marketing for SentreHEART, Inc. which is focused on the development of the first catheter based solution for left atrial appendage closure. From 2006 to 2011, he was the Vice President of Marketing, Clinical Affairs, and International Business at PEAK Surgical, Inc. PEAK was focused on the development and commercialization of an advanced energy surgical platform for multiple surgical specialties. He was part of the original management team that took PEAK from inception (2006) all the way to acquisition by Medtronic, Inc. in 2011. Prior to PEAK, he worked at ArthroCare Corporation (now SNN) in various marketing and international management roles.

To see this content, please login